INTARCIA THERAPEUTICS INC
United States of America (US)
OpenCorporation rating: 7.57 on 100
Ranking 2020: 568 on 602 companies
Primary and secondary NACE classification:
• Manufacture of pharmaceutical preparations (2120)
• Manufacture of pharmaceutical preparations (2120)
Company description
This company is engaged in developing innovative therapies utilizing the Medici Drug Delivery System - medicines that have the potential to transform the prevention and management of serious chronic diseases. It has its registered head office located in Boston, Massachusetts, United States. The company's novel technology platform, the Medici Drug Delivery System, comprised of three unique technologies: a stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures for up to three years or more; a matchstick-sized osmotic mini-pump that is placed just under the dermal layer of skin to deliver a continuous and consistent flow of medication; and a placement technology including proprietary tools designed to provide an optimal user experience. The therapies it develops: are based on promising therapeutic classes with proven clinical safety and activity; hold potential to represent significant improvements over the established standards of care; may qualify for accelerated development and regulatory pathways; and create proprietary product candidates, securing or extending exclusivity.
OpenCorporation questionnaire
The read only version of the questionnaire submitted to this company is publicly available: view questionnaire.